EuroValve 2016 program

March 10 - 11, 2016

www.eu rova l vecong ress .com

Hotel Bloom!, Brussels, BELGIUM

COURSE DIRECTORSPatrizio Lancellotti, Liege, Belgium

Khalil Fattouch, Palermo, ItalyGilbert Habib, Marseille, France

José Luis Zamorano, Madrid, SpainRaphael Rosenhek, Vienna, Austria

Scientific program endorsed by the EACVIand by the ESC Working Group on Valvular Heart Diseases

Edito

Welcome to EuroValve 2016!

It is a great pleasure to welcome you for this fourth edition in Brussels, the n°1 destination for congresses in Europe, which offers you an exciting cultural, artistic and socialscene at sensible prices.As you may know, we always intend to favour more interactivity and discussions, especially thanks to several symposia, industry symposia, controversies and round tables.Again, over 2 days, we will present an extensive program dedicated to valvular heart disease, focusing on genetics, surgery, epidemiology, transcatheter valve replacement, echocardiography and new imaging.This year, we are hosting the ePosters presentation on Thursday March 10 in the plenary room.Take your time to visit the exhibition and discover the Industry news as it is only thanks to their precious help that we could achieve our ambitious program and do not miss Abbott Vascular and Siemens symposia in the plenary room.We are very pleased to have you during two convivial days of fruitful teaching in Brussels.

Enjoy the congress!The course directors

Patrizio Lancellotti, Khalil Fattouch, Gilbert Habib,José Luis Zamorano and Raphael Rosenhek

FacultyJutta Bergler-Klein, Vienna, AustriaAlain Berrebi, Paris, FranceBernard Cosyns, Braine-L’Alleud, BelgiumMichele De Bonis, Milan, ItalyJean-Olivier Defraigne, Liege, BelgiumLaurent De Kerchove, Woluwe-Saint-Lambert, BelgiumVictoria Delgado, Leiden, The NetherlandsAlessandro Della Corte, Naples, ItalyErwan Donal, Rennes, FranceGilles Dreyfus, MonacoRaluca Elena Dulgheru, Brussels, BelgiumArturo Evangelista Masip, Barcelona, SpainMadalina Garbi, London, United KingdomAriana González-Gómez, Madrid, SpainBernard Iung, Paris, FranceJoëlle Kefer, Brussels, BelgiumPhilippe Kolh, Liege, BelgiumGiovanni La Canna, Milan, ItalyVictor Legrand, Liege, Belgium

Julien Magne, Limoges, FranceGérald Maurer, Vienna, AustriaThomas Modine, Lille, FranceJean-Luc Monin, Créteil, FranceCécile Oury, Liege, BelgiumAlessandro Parolari, Milan, ItalyAgnes Pasquet, Brussels, BelgiumPhilippe Pibarot, Quebec, CanadaLuc Piérard, Liege, BelgiumBernard Prendergast, London, United KingdomPrakash P. Punjabi, London, United KingdomMarc Radermecker, Liege, BelgiumNatzi Sakalihasan, Liege, BelgiumMaurice Sarano, Rochester, USAPilar Tornos, Barcelona, SpainPhilippe Unger, Brussels, BelgiumNico Van de Veire, Gent, BelgiumIsidre Villacosta, Madrid, Spain

Scientific program endorsed by the EACVI and by the ESC Working Group on Valvular Heart Diseases

FacultyJutta Bergler-Klein, Vienna, AustriaAlain Berrebi, Paris, FranceBernard Cosyns, Braine-L’Alleud, BelgiumMichele De Bonis, Milan, ItalyJean-Olivier Defraigne, Liege, BelgiumLaurent De Kerchove, Woluwe-Saint-Lambert, BelgiumVictoria Delgado, Leiden, The NetherlandsAlessandro Della Corte, Naples, ItalyErwan Donal, Rennes, FranceGilles Dreyfus, MonacoRaluca Elena Dulgheru, Brussels, BelgiumArturo Evangelista Masip, Barcelona, SpainMadalina Garbi, London, United KingdomAriana González-Gómez, Madrid, SpainBernard Iung, Paris, FranceJoëlle Kefer, Brussels, BelgiumPhilippe Kolh, Liege, BelgiumGiovanni La Canna, Milan, ItalyVictor Legrand, Liege, Belgium

Julien Magne, Limoges, FranceGérald Maurer, Vienna, AustriaThomas Modine, Lille, FranceJean-Luc Monin, Créteil, FranceCécile Oury, Liege, BelgiumAlessandro Parolari, Milan, ItalyAgnes Pasquet, Brussels, BelgiumPhilippe Pibarot, Quebec, CanadaLuc Piérard, Liege, BelgiumBernard Prendergast, London, United KingdomPrakash P. Punjabi, London, United KingdomMarc Radermecker, Liege, BelgiumNatzi Sakalihasan, Liege, BelgiumMaurice Sarano, Rochester, USAPilar Tornos, Barcelona, SpainPhilippe Unger, Brussels, BelgiumNico Van de Veire, Gent, BelgiumIsidre Villacosta, Madrid, Spain

Synoptic

THURSDAY MARCH 10 FRIDAY MARCH 1108:30 Opening ceremony

Patrizio Lancellotti, Khalil Fattouch, Gilbert Habib, José Luis Zamorano, Raphael Rosenhek

08:30 Innovation: new therapeutic approaches of valve disease Victoria Delgado, Luc Piérard

08:40 Symposium: the changing environment of valve disease Patrizio Lancellotti, José Luis Zamorano

09:00 Keynote LectureArturo Evangelista Masip, Natzi Sakalihasan

09:40 Improving risk stratification in asymptomatic mitral regurgitationJean-Olivier Defraigne, Jutta Bergler-Klein

09:55 Keynote lecture Gilles Dreyfus, Gilbert Habib

10:15 Coffee break in the exhibition hall

10:45 Controversies in aortic regurgitationVictor Legrand, Alain Berrebi


11:25 Industry symposium

Accuracy in valve measurements, what are the new trends?

11:40 Industry symposium

Does MitraClip have a survival benefit?12:25 Lunch break in the exhibition hall 12:40 Industry symposium

13:10 Lunch break in the exhibition hall

13:25 ESC 2015 guidelines. Endocarditis: evolution or revolution?Luc Piérard, Patrizio Lancellotti

14:05 Seminar TAVI: minimizing complicationsPatrizio Lancellotti, Gerald Maurer

14:45 Short Communications. Challenges in aortic stenosisAgnes Pasquet, Ariana González-Gómez

15:20 Challenges in the management secondary mitral regurgitationPrakash P. Punjabi, Michele De Bonis, Gilbert Habib16:00 Coffee break in the exhibition hall

16:30 Case presentations: challenges in infective endocarditisGilbert Habib, José Luis Zamorano

16:35 Closing remarks and awards ceremonyPatrizio Lancellotti, Khalil Fattouch, Gilbert Habib,

José Luis Zamorano, Raphael Rosenhek

17:30 Keynote lectureKhalil Fattouch, Arturo Evangelista Masip

18:00 e-Posters competition19:10 End of the sessions

www.eurovalvecongress.com

Thursday March 10, 2016

08:00 Welcome coffee in the exhibition hall

08:30 Opening ceremony Patrizio Lancellotti, Khalil Fattouch, Gilbert Habib,


08:40 Symposium: the changing environment of valve disease Chairmen: Patrizio Lancellotti, José Luis Zamorano08:40 The epidemic of valvular disease, Maurice Sarano09:00 Comorbidities and multiple valves: new challenges, Bernard Prendergast 09:20 The heart team and the heart valve clinic, Raphael Rosenhek09:40 Round table discussion with expert’s panel:

Luc Piérard, Philippe Pibarot, Jean-Luc Monin

09:55 Keynote lecture Chairmen: Gilles Dreyfus, Gilbert Habib09:55 Should we operate on tricuspid valve at the time of left-sided valve surgery?

Giovanni La Canna10:05 Round table discussion with expert’s panel:

Philippe Kolh, Khalil Fattouch, Nico Van de Veire, Alain Berrebi


10:45 Controversies in aortic regurgitation Chairmen: Victor Legrand, Alain Berrebi10:45 Paravalvular regurgitation is a risk factor following TAVI, Philippe Pibarot 11:05 Mild paravalvular regurgitation is not a risk factor following TAVI,

Thomas Modine

11:25 Industry symposium Accuracy in valve measurements, what are the new trends? 11:25 2D Pitfalls in measurements in Mitral Regurgitation, Gilbert Habib 11:40 How 3D can help, José Luis Zamorano 11:55 The aortic valve. Do we need 3D? Ariana González-Gómez 12:10 Do not forget left ventricle in valvulopathies, Julien Magne


13:25 ESC 2015 guidelines. Endocarditis: evolution or revolution? Chairmen: Luc Piérard, Patrizio Lancellotti13:25 Prophylaxis, Bernard Iung13:40 Embolic risk, Patrizio Lancellotti13:55 Diagnostic strategy, Pilar Tornos14:10 Endocarditis team and surgical indications, Gilbert Habib14:25 Round table discussion with expert’s panel

Prakash P. Punjabi, Maurice Sarano, Raluca Elena Dulgheru, Philippe Unger

14:45 Short Communications. Challenges in aortic stenosis Chairmen: Agnes Pasquet, Ariana González-Gómez14:45 Why and what to say to the interventionists? José Luis Zamorano15:00 Should we move toward low risk AS patients with TAVI? Joëlle Kefer 15:15 SAVR or TAVI in patients with previous CABG? Marc Radermecker 15:30 Is TAVI better than SAVR in patients with LV dysfunction? Philippe Pibarot 15:45 ”Valve in Valve” interventions: which is the appropriate patient to select? TBC


16:30 Case presentations: challenges in infective endocarditis Chairmen: Gilbert Habib, José Luis Zamorano 16:30 Endocarditis in the intensive care, Bernard Cosyns16:45 Pacemaker lead endocarditis, Isidre Villacosta17:00 TAVI endocarditis, Gilbert Habib17:15 Marantic endocarditis, Erwan Donal

17:30 Keynote lecture Chairmen: Khalil Fattouch, Arturo Evangelista Masip 17:30 Aortic valve repair: state of the art? Laurent De Kerchove17:45 Round table discussion with expert’s panel

Natzi Sakalihasan, Alain Berrebi, Alessandro Della Corte

18:00 Eposters competition (p 8-11) Chairmen: Erwan Donal, Bernard Cosyns


Friday March 11, 2016

08:00 Welcome coffee in the exhibition hall

08:30 Innovation: new therapeutic approaches of valve disease Chairmen: Victoria Delgado, Luc Piérard08:30 Percutaneous mitral valve repair, Khalil Fattouch08:50 Round table discussion with expert’s panel

Jose Luis Zamorano, Thomas Modine, Ariana González-Gómez

09:00 Keynote Lecture Chairmen: Arturo Evangelista Masip, Natzi Sakalihasan09:00 The bicuspid aortic valve, Jean-Luc Monin09:20 Round table discussion with expert’s panel

Agnes Pasquet, Khalil Fattouch

09:40 Improving risk stratification in asymptomatic mitral regurgitation Chairmen: Jean-Olivier Defraigne, Jutta Bergler-Klein09:40 Stress echocardiography, Raluca Elena Dulgheru09:55 Neuro-hormones, Julien Magne10:10 Myocardial fibrosis by MRI, Victoria Delgado10:25 Watchful waiting? Raphael Rosenhek10:40 Current gold standard in primary MV repair: importance of patient selection,

Alessandro Parolari10:55 Round discussion with expert’s panel

Cécile Oury, Madalina Garbi


11:40 Industry symposium Does MitraClip have a survival benefit? Chairman: José Luis Zamorano11:40 Introduction, José Luis Zamorano11:50 Who can benefit from the MitraClip Therapy? Philippe Debonnaire12:00 Does MitraClip have a survival benefit? Martin Swaans12:10 Patient management after MitraClip Therapy, Victoria Delgado12:20 Conclusions, José Luis Zamorano

12:40 Industry symposium Anatomical intelligence in Ultrasound, how technology meets clinical practice Endocarditis, Gilbert Habib MV, the 3D perspective, Patrizio Lancelloti HM and EF, clinical scenarios, José Luis Zamorano Fusion imaging in the Cath Lab, the real deal? José Luis Zamorano


14:05 Seminar TAVI: minimizing complications Chairmen: Patrizio Lancellotti, Gerald Maurer14:05 Vascular access, Joëlle Kefer14:20 Stroke Michael, Thomas Modine14:35 Permanent pacing, Joëlle Kefer14:50 Paravalvular leak, José Luis Zamorano15:05 Round discussion with expert’s panel

Luc Piérard, Ariana González-Gómez

15:20 Challenges in the management secondary mitral regurgitation Chairmen: Michele De Bonis, Gilbert Habib15:20 Moderate or severe? Khalil Fattouch15:35 Guidelines in perspective? Luc Piérard15:50 Is there yet a place for surgical repair? Michele De Bonis16:05 Reshape/Coapt: do we need more? Jose Luis Zamorano16:20 Round discussion with expert’s panel

Khalil Fattouch, Jutta Bergler-Klein

16:35 Closing remarks and awards ceremony Patrizio Lancellotti, Khalil Fattouch, Gilbert Habib,



ePosters competition

18:00 Novel design for bileaflet mechanical heart valves and its hemodynamic performance under physiological condition

Nima Mirkhani1, Mohammad Reza Davoudi2, Pedram Hanafizadeh1, Daryoosh Javidi3, Niloofar Saffarian4

1. University of Tehran, Islamic Republic of Iran

2. Katholieke Universiteit Leuven, Belgium

3. Department of Cardiac Surgery, Pars Hospital, Tehran, Islamic Republic of Iran

4. Cardiovascular Department, Pars Hospital, Tehran, Islamic Republic of Iran

18:03 Heart sarcoma invasive mitral valve Redha Lakehal, Aimer Farid, Bouharagua Rabeh, Boutamina Lilya,

khacha khaled, Boukharoucha Radouane, Bendjaballah Soumaya, Aziza Baya, Brahami Abdelmalek

Ehs el riadh, CONSTANTINE, Algeria

18:06 Thrombosis of heart valve prosthesis in pregnant women Redha Lakehal, Boukharoucha Radouane, Aimer Farid, Bouharagua Rabeh,

Babouri Abdelrahmen, Boutamina Lilya, Aziza Baya, Bendjaballah Soumaya, Brahami Abdelmalek

Ehs el riadh, CONSTANTINE, Algeria

18:09 Prosthetic valve thrombosis Redha Lakehal, Boukharoucha Radouane, Aimer Farid, Bouharagua Rabeh,

Brahami Abdelmalek Ehs el riadh, CONSTANTINE, Algeria

18:12 Aortic valve repair versus replacement in laubry pezzi syndrome Redha Lakehal, Bouharagua Rabeh, Aimer Farid, Boukharoucha Radouane,

Brahami Abdelmalek Ehs el riadh, CONSTANTINE, Algeria

18:15 Epidemiological and clinical aspects of 88 cases with rheumatic mitral valve disease (RMD)

Noura Elazaoui, Leila Azzouzi, Malika Noureddine, Rachida Habbal CHU Ibn Rochd, Casablanca, Morocco

18:18 Brucella tricuspid endocarditis Redha Lakehal, Aimer Farid, Bouharagua Rabeh, Boukharoucha Radouane,

Boukharoucha Radouane Ehs el riadh, CONSTANTINE, Algeria

18:21 Posterior aortic enlargement in women with aortic annulus at 15 mm Redha Lakehal, Aimer Farid, Bouharagua Rabeh, Boukharoucha Radouane,

Brahami Abdelmalek, Boukharoucha Radouane, Brahami Abdelmalek Ehs el riadh, CONSTANTINE, Algeria

18:24 Rheumatic mitral stenosis in adult people in Casablanca (Morocco) Noura Elazaoui, Leila Azzouzi, Malika Noureddine, Rachida Habbal CHU Ibn Rochd, Casablanca, Morocco

18:27 Transient acute mitral regurgitation (TAMR): a new entity responsible for acute heart failure in patients with preserved left ventricular ejection fraction

Olivier Milleron1, Claire Bouleti1, Serge Mazouz2, Eric Brochet1, Whalid Ghodbane3, David Messika-Zeitoun1, Simon Cattan2, Alec Vahanian1, Bernard Iung1, Guillaume Jondeau1

1. Service de Cardiologie Hopital Bichat, Paris, France

2. Service de Cardiologie GHI Le Raincy-Montfermeil, France

3. Service de Chirurgie Cardiaque. Hôpital Bichat, Paris, France

18:30 Investigation of aortic mechanical heart valve effects on the coronary arteries flow rate and potential risk of the atherosclerosis

Nima Mirkhani1, Mohammad Reza Davoudi2, Pedram Hanafizadeh1, Daryoosh Javidi3, Niloofar Saffarian4

1. University of Tehran, Islamic Republic of Iran

2. Katholieke Universiteit Leuven, Belgium

3. Department of Cardiac Surgery, Pars Hospital, Tehran, Islamic Republic of Iran

4. Cardiovascular Department, Pars Hospital, Tehran, Islamic Republic of Iran

18:33 Stress echocardiography: a very useful test in the management of patients with mitral valve stenosis

Oriol de Diego Soler, Elena Ferrer Sistach, Nuria Vallejo Camazon, Jorge Lopez-Ayerbe, Albert Teis Soley, Francisco Gual Capllonch, Silvia Serrano Garcia, Eva Bernal Labrador, Gladys Junca Puig, Antoni Bayes-Genis

Hospital Universitari Germans Trias i Pujol, Badalona, Spain

18:36 Tricuspid tissue valve re-operation in patient with a normally functioning mechanical mitral valve

Sofija Popevska, Darko Anic University Clinic for Cardiac Surgery Rebro, Zagreb, Croatia

18:39 Durability of mechanical mitral prosthesis: do we test the time? Sofija Popevska University Clinic for Cardiac Surgery Rebro, Zagreb, Croatia

18:42 Fusion of x-ray and real time echocardiography during TAVI Ilaria Boretti, Ariana González-Gómez, Covadonga Fernández-Golfín,

Luisa Salido-Tahoces, Rosa Ana Hernández-Antolín, Eduardo Casas-Rojo, Rocio Hinojar-Baydes, José Luis Zamorano

Department of Cardiology-Ramon y Cajal University Hospital, Madrid, Spain

Sign up under the ‘Stay Alert’ heading at: ehjcimaging.oxfordjournals.org

Stay alertKeep up to date with the highest quality material,

both scientific and clinical, from all areas of cardiovascular imaging with email table of

contents alerts from the European Heart Journal – Cardiovascular Imaging

At the heart of Cardiology

ePosters competition

18:45 Ball thrombus with recent cardioembolic stroke: case report and brief review of the literature

Noura Elazaoui, Leila Azzouzi, Malika Noureddine, Rachida Habbal CHU Ibn Rochd, Casablanca, Morocco

18:48 Characteristics and outcomes of asymptomatic severe aortic stenosis patients with preserved left ventricular ejection fraction according to the flow and gradient classification

Carlos Izurieta, Juan Manuel Monteagudo-Ruiz, Ariana González-Gómez, Covadonga Fernández-Golfin, Ana García-Martín, Rocío Hinojar-Baydes, Eduardo Casas-Rojo, José Julio Jiménez-Nacher, José Luis Zamorano

Hospital Universitario Ramón y Cajal, Madrid, Spain

18:51 Prosthetic pulmonary valve and pulmonary conduit endocarditis: clinical, microbiological and echocardiographic features in adults

William Miranda, Heidi Connolly, Crystal Bonnichsen, Daniel DeSimone, Joseph Dearani, Joseph Maleszewski, Kevin Greason, Walter Wilson, Larry Baddour

Mayo Clinic, Rochester, United States

18:54 Emergent surgery in infective endocarditis in a tertiary hospital Nuria Vallejo Camazon1, Xavier Armario1, Oriol de Diego1, Francisco Gual1,

Albert Teis1, Jorge Lopez Ayerbe1, Cinta LLibre1, Lluisa Pedro Botet2, Raquel Nuñez Aragon2, Antoni Bayes Genis1

1. Cardiology. Hospital Germans TRias i Pujol, Barcelona, Spain

2. Infectious Diseases department.Hopsital Germans Trias i Pujol, Badalona, Spain

18:57 Clinical and epidemiological profile of native infective endocarditis in a tertiary center; outcome changes after multidisciplinary team aproach

Nuria Vallejo1, Oriol De Diego1, Xavier Armario1, Lurdes Mateu2, Sonia Molinos3, Elisabet Berastegui4, Elena Ferrer1, Antoni Bayes Genis1

1. Cardiology department. Hospital Germans Trias i Pujol, Badalona, Spain

2. Infectious diseases. Hospital Germans TRias i Pujol, Badalona, Spain

3. Microbiology. Hospital Germans Trias i Pujol, Badalona, Spain

4. Cardiaca Surgery. Hospital Germans TRias i Pujol, Badalona, Spain

19:00 Pseudoaneurysm of valsalva sinus in a brucella infected native aortic valve Daniela Teferici, Edvin Prifti, Amanda Lloji, Lidra Gjyli UHC “Mother Theresa”, Tirana, Albania

19:10 End of the sessions

Sign up under the ‘Stay Alert’ heading at: ehjcimaging.oxfordjournals.org

Stay alertKeep up to date with the highest quality material,

both scientific and clinical, from all areas of cardiovascular imaging with email table of

contents alerts from the European Heart Journal – Cardiovascular Imaging

At the heart of Cardiology

Notes

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Information

Congress venue: Hotel Bloom, Brussels, BELGIUMRue Royale 2501210 Brussels, BelgiumPhone: +3222206611www.hotelbloom.com

REGISTRATION DESK OPENING HOURS

Thursday March 10 07.30 - 19.30Friday March 11 07.30 - 17.00

EVENT COORDINATORS’ CONTACTS

Project manager Stéphanie Meyer + 33 646 10 48 26

Managing directorVérane Bergeron Moreau + 33 621 78 87 16

References1. St. Jude Medical. Trifecta™ Valve. Pre-Market Approval Application Summary of Safety and Effectiveness Data. P100029. 2011.2. St. Jude Medical. Trifecta™ Valve. Clinical Compendium. Five-Year Data. 2014. ID-2000385 B EN (06/14).3. Edwards Lifesciences Corporation. Carpentier-Edwards Magna Ease™ Pericardial Aortic Bioprosthesis, Model 3300TFX. Instructions for Use. 2009. Echo follow-up at one year. 4. Medtronic, Inc. (ATS Medical). 3f™ Aortic Bioprosthesis. Pre-Market Approval Application Summary of Safety and Effectiveness Data, P060025. 2008. Echo follow-up at one year.5. Medtronic, Inc. Medtronic Mosaic™ Porcine Bioprosthesis. Pre-Market Approval Application Summary of Safety and Effectiveness Data. P990064. 2000. Echo follow-up at one year.6. CarboMedics, Inc., Sorin. Mitroflow™ Aortic Pericardial Heart Valve. Pre-Market Approval Application Summary of Safety and Effectiveness Data. P060038. 2007. Echo follow-up at one year.7. St. Jude Medical. Trifecta™ Valve. 2010. Data on file.Rx Only Brief Summary: Prior to using these devices, please review the Instructions for Use for a complete listing of indications, contraindications, warnings, precautions, potential adverse events and directions for use. Indications: The Trifecta™ Valve is indicated as a replacement for a diseased, damaged, or malfunctioning native or prosthetic aortic heart valve. Adverse events potentially associated with the use of bioprosthetic heart valves include: angina, cardiac arrhythmias, endocarditis, heart failure, hemolysis, hemolytic anemia, hemorrhage, leak (transvalvular or perivalvular), myocardial infarction, nonstructural dysfunction (entrapment by pannus or suture, inappropriate sizing or positioning, or other), prosthesis regurgitation, stroke, structural deterioration (calcification, leaflet tear, perforation, or other), thromboembolism and valve thrombosis. It is possible that these complications could lead to reoperation, explantation, permanent disability or death. Long-term low dose aspirin, unless contraindicated, is recommended for all patients with bioprosthetic valves. Long-term anticoagulant therapy, unless contraindicated, is recommended for all patients with bioprosthetic valves who have risk factors for thromboembolism. Please see the Instructions for Use (IFU) for a full description of indications, contraindications, side effects, precautions, warnings and Instructions for Use. Unless otherwise noted, ™ indicates that the name is a trademark of, or licensed to, St. Jude Medical or one of its subsidiaries. ST. JUDE MEDICAL and the nine-squares symbol are trademarks and service marks of St. Jude Medical, Inc. and its related companies. © 2015 St. Jude Medical, Inc. All Rights Reserved. Product referenced is approved for CE Mark. SJM-TRF-1214-0015(2)b | Item approved for international use.

The Trifecta™ Valve from St. Jude Medical was designed to deliver exceptional hemodynamic performance and durability to stand the test of time. The Trifecta™ Valve consistently mimics the flow of a native healthy heart valve.

Bench testing predicted excellent hemodynamics and durability,1 while clinical data from a prospective multi-center study delivered the proof.2

PROMISE Exceptional hemodynamics

PROVEN The lowest hemodynamic gradients in the market, size-for-size among tissue heart valves1,3-6

PROMISE Excellent durability; 99.2% freedom from SVD at 5 years7

PROVEN 99.7% freedom from SVD at 5 years2

Learn more at sjm.com/trifecta

WHY NOT OFFER YOUR PATIENTS A VALVE PROVEN TO PERFORM LIKE A NATIVE HEALTHY HEART VALVE?

Plenary room

23

4

51

Preview

CloakroomBuffet

Desk

Table futuremeeting

Buffet

office

ACKNOWLEDGEMENTS 2016

Exhibition hallEXHIBITION TIMES Thursday March 10 08.00 - 16.30Friday March 11 08.00 - 14.00

Booth Company

1 Abbott Vascular2 GE Healthcare3 Medtronic4 LivaNova5 St. Jude Medical

Notes

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .


ORGANIZATION: divine [id] agency • Stéphanie Meyer: [email protected] • Mob. +33 (0) 646 10 48 26• Vérane Bergeron Moreau: [email protected]• 17, rue Venture - 13001 Marseille, France• Tel. +33 (0) 491 57 19 60 • Fax +33 (0) 491 57 19 61 • www.divine-id.com

Visa Mdeon n° 16/V2/8598/004974

EuroValve 2016 program

Documents

Transcript of EuroValve 2016 program